17327-35-4

Basic information

• Product Name: 1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)-
• Synonyms: 1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)-
• CAS NO: 17327-35-4
• Molecular Formula: C₅H₆F₆O
• Molecular Weight: 196.0909592
• Mol File: 17327-35-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)-(17327-35-4)
• EPA Substance Registry System: 1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)-(17327-35-4)

Safety Data

• Hazardous Substances Data: 17327-35-4(Hazardous Substances Data)

Usage

Description

1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)is a chemical compound with the molecular formula C5H3F7O. It is characterized by its trifluoromethyl groups and a butanol backbone, which contribute to its unique properties and potential applications.

Uses

Used in Pharmaceutical Industry:
1-Butanol, 4,4,4-trifluoro-3-(trifluoromethyl)is used as a component in the pharmaceutical industry for the development of stable pharmaceutical aerosols intended for inhalation. Its unique chemical structure allows it to contribute to the stability and effectiveness of these aerosols, making it a valuable asset in the creation of inhalable medications for various respiratory and other health conditions.

Upstream product

• 1513-60-6 ethyl 4,4,4-trifluoro-3-(trifluoromethyl)crotonate 
• 17327-34-3 ethyl 4,4,4-trifluoro-3-(trifluoromethyl)butyrate 

Downstream Products

• 1026237-95-5 3-Methoxy-4-[1-methyl-5-(4,4,4-trifluoro-3-trifluoromethyl-butylcarbamoyl)-1H-indol-3-ylmethyl]-benzoic acid methyl ester 
• 1026689-32-6 3-Methoxy-4-[1-methyl-5-(4,4,4-trifluoro-3-trifluoromethyl-butylcarbamoyl)-1H-indol-3-ylmethyl]-benzoic acid 

Relevant articles and documents

Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-indolecarboxamides: Identification of 4--1-methylindol-3-yl>methyl>-3-methoxy-N-benzamide, ...

The continued exploration of a series of 3-(arylmethyl)-1H-indole-5-carboxamides by the introduction of fluorinated amide substituents has resulted in the discovery of 4--1-methylindol-3-yl>methyl>-3-methoxy-N-benzamide (38p, ZENECA ZD 3523), which has been chosen for clinical evaluation.This compound exhibited a Ki of 0.42 nM for displacement of LTD4 on guinea pig lung membranes, a pKB of 10.13 +/- 0.14 versus LTE4 on guinea pig trachea, and an oral ED50 of 1.14 μmol/kg opposite LTD4-induced bronchoconstriction in guinea pigs.The R enantiomer was found to be modestly more potent than the S enantiomer 38o.Modification of the amide substituent to afford achiral compounds was unsuccessful in achieving comparable levels of activity.Profiling of 38p opposite a variety of functional assays has demonstrated the selectivity of this compound as a leukotriene receptor antagonist.The enantioselective synthesis of 38p, which employed a diastereoselective alkylation of (4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone (27) as the key step to establish the chirality of the amide substituent, provided an efficient route for generating 38p in >99percent enantiomeric purity.